Comparison of two high dose rate intracavitary brachytherapy regimens in treatment of cervical cancer: a preliminary report.

Content Provider	Europe PMC
Author	Krishna, Abhishek Hasib, AG Fernandes, Donald Athiyamaan, M. S. Rao, Sandesh Shankar, Sharaschandra Ali, Mohsina Priyadarshini, Hepsiba Sophia, Maria Shridhar, CH George, Seby Babu, Amrutha Banerjee, Sourjya Sunny, Johan Srinivas, Challapalli Lobo, Dilson
Abstract	BackgroundTo assess and compare the local control and toxicities between HDR Intracavitary Brachytherapy with 7.5 Gy and 9 Gy per fraction after EBRT in treatment of carcinoma cervix.MethodologyA total of 180 patients were randomly assigned to 2 arms. Arm A received HDR intracavitary brachytherapy with a dose of 7.5 Gy per fraction, 1 fraction per week for 3 fractions and Arm B received 9 Gy per fraction, 1 fraction per week for 2 fractions. Patients were evaluated on follow up for assessment of local control and toxicities.ResultsThe median follow up was 12 months (6–18 months). In arm A 89% of the patient had complete response and 11% had recurrence or metastasis. In arm B 93% of the patient had complete response and 7% had recurrence or metastasis. Grade 2/3 diarrhoea was seen in 4.4% of patients in Arm A and in 7.7% in Arm B. Grade 2/3 proctitis was seen in 3.3% of patients in 7.5 Gy arm and in 6.6% in 9 Gy arm. One patient in each arm had grade 1 haematuria. The overall duration of treatment was significant lower in Arm B compared to Arm A (59 days vs 68 days, p = 0.01).ConclusionThe result of this clinical study shows that Intracavitary brachytherapy with a dose of 9 Gy per fraction is non inferior to other schedules in term of local control and does not result in increased toxicity.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10060448&blobtype=pdf
Journal	Discover. Oncology [Discov Oncol]
Volume Number	14
DOI	10.1007/s12672-023-00646-x
PubMed Central reference number	PMC10060448
Issue Number	1
PubMed reference number	36988721
e-ISSN	27306011
Language	English
Publisher	Springer US
Publisher Date	2023-03-29
Publisher Place	New York
Access Restriction	Open
Rights License	Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2023
Subject Keyword	Carcinoma cervix Brachytherapy Intracavitary radiotherapy
Content Type	Text
Resource Type	Article
Subject	Endocrinology Endocrinology, Diabetes and Metabolism Oncology Cancer Research Endocrine and Autonomic Systems